1-methyldecahydroquinoline | 64599-88-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉类
• 英文名称: 1-methyldecahydroquinoline
• 英文别名: N-methyldecahydroquinoline；1-methyl-decahydro-quinoline；1-Methyl-decahydrochinolin；1-Methyldecahydrochinolin；1-methyl-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline
• CAS: 64599-88-8；87207-57-6
• 化学式: C₁₀H₁₉N
• mdl: MFCD26098606
• 分子量: 153.268
• InChiKey: AAARTTJTRNAYHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-methyldecahydroquinoline 生成 perfluoro-N-methyl-decahydroquinoline
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  聚合甲醛 、 十氢喹啉 在 甲酸 作用下， 以 水 为溶剂， 反应 24.0h， 生成 1-methyldecahydroquinoline
  参考文献：
  名称：

  通过使用铜/中等受阻硝基氧自由基（DMN-AZADO或1-Me-AZADO）将叔胺进行甲基选择性甲基氧化为甲酰胺。

  摘要：

  叔胺的甲基选择性α-加氧是合成甲酰胺同时保留胺底物骨架的极具吸引力的方法。因此，开发能够使用分子氧（O 2）作为末端氧化剂来促进在N-甲基位置上的区域选择性α-氧化的有效催化剂是重要的课题。在这项研究中，我们成功地通过使用Cu / nitroxyl自由基催化剂系统开发了一种高度区域选择性和高效的叔胺好氧甲基选择性α-加氧方法。使用中等受阻的硝酰基自由基，例如1,5-二甲基-9-金刚烷金刚烷N-氧基（DMN-AZADO）和1-甲基-2-氮杂金刚烷N-氧基（1-Me-AZADO）对于有效地促进氧合作用，主要是因为这些N-羟基比受阻较少的N-羟基具有更长的寿命。将各种类型的叔N-甲胺选择性地转化为相应的甲酰胺。还根据实验证据以及DFT计算讨论了合理的反应机理。该催化剂体系的高区域选择性源自胺-N-氧基相互作用的空间限制。

  DOI：

  10.1002/anie.201909005

文献信息

• BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS
  申请人：HOLTMAN Joseph R.

  公开号：US20110166177A1

  公开（公告）日：2011-07-07

  Provided are methods for using bis-quaternary ammonium compounds to treat inflammatory pain, neuropathic pain and nociceptive pain.

  提供了使用双季铵化合物治疗炎症性疼痛、神经病理性疼痛和伤害性疼痛的方法。
• COLORING CURABLE RESIN COMPOSITION, CURED FILM, COLOR FILTER, METHOD FOR MANUFACTURING COLOR FILTER, SOLID-STATE IMAGING DEVICE, IMAGE DISPLAY DEVICE, COMPOUND, AND CATION
  申请人：FUJIFILM Corporation

  公开号：US20160376234A1

  公开（公告）日：2016-12-29

  The present invention provides a colored curable resin composition that exhibits good heat resistance and durability in a sputtering process, a cured film, a color filter, a method for manufacturing a color filter, a solid-state image device, an image display device, a compound, and a cation. The colored curable resin composition contains a colorant represented by Formula (1), Formula (2), or Formula (3), a resin, a polymerizable compound, and a polymerization initiator. In Formula (1), R 101 and R 102 each independently represent a hydrogen atom or a substituent, R 103 to R 106 each independently represent a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group, R 107 to R 111 each independently represent a hydrogen atom or a substituent, n1 to n4 each independently represent an integer of 0 to 4, n5 represents an integer of 0 to 6, X represents an anion or is not present, and at least one of R 101 , . . . , or R 111 includes an anion; and in the case where R 101 and R 102 represent hydrogen atoms, R 103 represents an aryl group having a substituent at at least the ortho-position.

  本发明提供了一种在溅射工艺中具有良好耐热性和耐久性的着色可固化树脂组合物、固化膜、色滤光器、制造色滤光器的方法、固态图像设备、图像显示设备、化合物和阳离子。该着色可固化树脂组合物含有由公式(1)、公式(2)或公式(3)表示的着色剂、树脂、可聚合化合物和聚合引发剂。在公式(1)中，R101和R102各自独立地表示氢原子或取代基，R103至R106各自独立地表示氢原子、烷基、芳基或杂芳基，R107至R111各自独立地表示氢原子或取代基，n1至n4各自独立地表示0至4的整数，n5表示0至6的整数，X表示阴离子或不出现，且至少R101、…或R111中包括阴离子；且在R101和R102表示氢原子的情况下，R103表示在至少邻位具有取代基的芳基。
• [EN] AMIDO-THIOPHENE COMPOUNDS AND THEIR USE AS 11-BETA-HSD1 INHIBITORS<br/>[FR] COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BÊTA-HSD1
  申请人：UNIV EDINBURGH

  公开号：WO2009074789A1

  公开（公告）日：2009-06-18

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. Formula (I).

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些酰胺噻吩化合物，其中包括抑制11β-羟基类固醇脱氢酶1（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基类固醇脱氢酶1；治疗通过抑制11β-羟基类固醇脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和心血管疾病，如缺血性（冠状）心脏病；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。公式（I）。
• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：POLYPHOR AG

  公开号：US20150051183A1

  公开（公告）日：2015-02-19

  The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

  公式（I）的构象受限、空间定义的大环环系统由三个不同的分子部分组成：模板A、构象调节剂B和桥C。由这种环系统I描述的大环可通过并行合成或溶液中或固相上的组合化学轻松制造。它们被设计用于与各种特定生物靶标类相互作用，例如在G蛋白偶联受体（GPCR）上的激动或拮抗活性，酶的抑制活性或抗菌活性。特别是，这些大环显示对亚型1的内皮素转化酶（ECE-1）和/或半胱氨酸蛋白酶卡特普辛S（CatS）的抑制活性，和/或作为催产素（OT）受体、促甲状腺释放激素（TRH）受体和/或白三烯B4（LTB4）受体的拮抗剂，和/或作为瘤胃素3（BB3）受体的激动剂，和/或对至少一种细菌菌株显示抗菌活性。因此，它们显示出作为各种疾病药物的巨大潜力。
• SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS
  申请人：MESSINGER Josef

  公开号：US20080255075A1

  公开（公告）日：2008-10-16

  Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  公式（I）中的替代雌三烯化合物在治疗中很有用，特别是在治疗或抑制需要抑制17β-羟基类固醇脱氢酶（17β-HSD）类型1、类型2和/或类型3酶的类固醇激素依赖性疾病方面，以及它们的盐、含有这种化合物的药物组合物和制备这种化合物的方法。